

| Medication in Green Zone | | Change in Yellow Zone (all inhaler recommendations are for 7-14 days) | |
|---|-----------------------|---|--|
| DEVICE | DOSING REGIMENS | YELLOW ZONE ESCALATION | |
| | | ICS | |
| Flovent HFA (Fluticasone propionate) | 50 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 125 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 125 mcg 2 puffs BID | Increase to 4 puffs QID | |
| | 250 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 250 mcg 2 puffs BID | Increase to 4 puffs QID | |
| Flovent Diskus (Fluticasone propionate) | 100 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 250 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 500 mcg 1 puff BID | Increase to 2 puffs BID | |
| Arnuity Ellipta (Fluticasone furoate) | 100 mcg 1 puff daily | Option 1: Increase to 4 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |
| | 200 mcg 1 puff daily | Option 1: Increase to 4 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |
| Pulmicort Turbuhaler (Budesonide) | 100 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 200 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 400 mcg 1 puff BID | Increase to 3 puffs BID | |
| QVAR MDI (Beclomethasone) | 50 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 100 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 100 mcg 2 puffs BID | Prednisone 30-50 mg daily ² | |
| Alvesco MDI (Ciclesonide) | 100 mcg 1 puff daily | Increase to 4 puffs daily | |
| | 200 mcg 1 puff daily | Increase to 4 puffs daily | |
| | 200 mcg 2 puffs daily | Increase to 4 puffs BID | |
| Asmanex Twisthaler (Mometasone) | 200 mcg 1 puff daily | Increase to 4 puffs daily | |
| | 400 mcg 1 puff daily | Option 1: Increase to 4 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |
| Aermony Respiclick (fluticasone propionate) | 55 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 113 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 232 mcg 1 puff BID | Increase to 2 puffs BID | |



| Medication in Green Zone | | Change in Yellow Zone (all inhaler recommendations are for 7-14 days) | |
|--|--------------------------|---|--|
| DEVICE | DOSING REGIMENS | YELLOW ZONE ESCALATION | |
| | | ICS/LABA | |
| Advair Diskus (Fluticasone propionate/Salmeterol) | 100/50 mcg 1 puff BID | Add Flovent Diskus 100 mcg 3 puffs BID | |
| | 250/50 mcg 1 puff BID | Add Flovent Diskus 250 mcg 3 puffs BID | |
| | 500/50 mcg 1 puff BID | Add Flovent Diskus 500 mcg 1 puff BID | |
| Advair HFA (Fluticasone propionate/Salmeterol) | 125/25 mcg 2 puffs BID | Add Flovent HFA 250 mcg 3 puffs BID | |
| | 250/25 mg 2 puffs BID | Add Flovent HFA 250 mcg 2 puffs BID | |
| Symbicort Turbuhaler (Budesonide/Formoterol) | 100/6 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 200/6 mcg 1 puff BID | Increase to 4 puffs BID | |
| | 200/6 mcg 2 puffs BID | Add Pulmicort Turbuhaler 400 mcg 2 puffs BID | |
| Zenhale MDI (Mometasone Furoate/Formoterol) | 100/5 mcg 2 puffs BID | Option 1: Change to Zenhale MDI 200/5 mcg 4 puffs BID ¹ | Option 2: Prednisone 30-50 mg daily ² |
| | 200/5 mcg 2 puffs BID | Prednisone 30-50 mg daily ² | |
| Breo Ellipta (Fluticasone furoate/Vilanterol) | 100/25 mcg 1 puff daily | Option 1: Add Arnuity Ellipta 100 mcg 3 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |
| | 200/25 mcg 1 puff daily | Option 1: Add Arnuity Ellipta 200 mcg 3 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |
| Wixela Inhub (fluticasone propionate/salmeterol) | 100/50 mcg 1 puff BID | Add Flovent Diskus 100 mcg 3 puffs BID | |
| | 250/50 mcg 1 puff BID | Add Flovent Diskus 250 mcg 3 puffs BID | |
| | 500/50 mcg 1 puff BID | Add Flovent Diskus 500 mcg 1 puff BID | |
| Atectura Breezhaler (indacaterol/mometasone) | 150/80 mcg 1 puff daily | Option 1: Increase to 4 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |
| | 150/160 mcg 1 puff daily | Option 1: Increase to 4 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |
| | 150/320 mcg 1 puff daily | Option 1: Increase to 4 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily ² |

ASTHMA ACTION PLAN YELLOW ZONE GUIDE (AGES 16±YEARS)



| Medication in Green Zone | | Change in Yellow Zone (all inhaler recommendations are for 7-14 days) | | | | |
|---|---|--|--|--|--|--|
| DEVICE | DOSING REGIMENS | YELLOW ZONE ESCALATION | | | | |
| ICS/LABA/LAMA | | | | | | |
| Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) | 100/62.5/25 mcg 1 puff daily | Option 1: Add Arnuity Ellipta 100 mcg 3 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily for 5-7 days ² | | | |
| | 200/62.5/25 mcg 1 puff daily | Option 1: Add Arnuity Ellipta 200 mcg 3 puffs daily ¹ | Option 2: Prednisone 30-50 mg daily for 5-7 days ² | | | |
| Enerzair Breezhaler (indacaterol/glycopyrronium/mometasone) | 150/50/160 mcg 1 puff daily | Option 1: Add Atectura Breezhaler 150/320 mcg 3 puffs daily ^{1*} | Option 2: Prednisone 30-50 mg daily ² | | | |
| | | | | | | |
| Special considerations | | | | | | |
| In patients with a history of sudden and seve | Prednisone 30-50 mg daily for 5-7 days as first line therapy ² | | | | | |
| If patient fails to improve clinically within 2-3 deterioration, and/or has a peak expiratory flo | Prednisone 30-50 mg daily for 5-7 days as rescue (second line) therapy ² | | | | | |

- 1 This dose exceeds product monograph total daily dose limits intended for chronic daily use. A short term dose increase beyond these limits is unlikely to carry any significant safety risks. The decision to pursue this approach should be based on patient and clinician comfort.
- 2 Ask patients to contact the health care provider to consider a prednisone prescription and/or provide a standing prescription for prednisone 30-50mg daily for 5-7 days. Ensure that patients are appropriately counseled about the risks of short-term prednisone use.
- * For Enerzair Breezhaler. due to pharmaceutical interactions between the drugs contained in Enerzair Breezhaler, the 160mcg dose of mometason delivered in this inhaler is equivalent to the 320mcg dose of mometasone delivered in the Atectura Breezhaler device, and so in order to accurately quadruple the dose of mometasone, this dose of Atectura Breezhaler must be used.

Adapted from: Kouri A, Boulet L-P, Kaplan A, Gupta S. An Evidence-based, point-of-care tool to guide completion of asthma action plans in practice. Eur Respir J 2017.